Giovanni Ramirez
Research Subjects
Giovanni Ramirez has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Kyle Ray
Colorado Chromatography Labs
8 shared publications - Tesfay Tesfatsion
Colorado Chromatography Labs
8 shared publications - Westley Cruces
Colorado Chromatography Labs
8 shared publications - Monica Pittiglio
Colorado Chromatography Labs
7 shared publications - Maite L. Docampo Palacios
Colorado Chromatography Labs
4 shared publications - Alex Okhovat
Colorado Chromatography Labs
3 shared publications
Latest Publications
- Open Access
- 21 August 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Modified Pickering Catalysis: Green Transfer Hydrogenation of the Tri-substituted Olefin of Tetrahydocannabinol
Green transfer hydrogenation of the trisubstituted olefin within the tetrahydrocannabinol scaffold, has been performed using minimal amount of organic solvent in water, on the basis of a modified Pickering catalysis, with greater selectivity over standard industrial conditions with decreased reaction times under ambient conditions. Examples of various solvents, surfactants, and observation of europium in the selectivity of the hydrogenated products are given.
- 21 August 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessModified Pickering Catalysis: Green Transfer Hydrogenation of the Tri-substituted Olefin of Tetrahydocannabinol
Green transfer hydrogenation of the trisubstituted olefin within the tetrahydrocannabinol scaffold, has been performed using minimal amount of organic solvent in water, on the basis of a modified Pickering catalysis, with greater selectivity over standard industrial conditions with decreased reaction times under ambient conditions. Examples of various solvents, surfactants, and observation of europium in the selectivity of the hydrogenated products are given.
- Open Access
- 10 June 2024
- Published by American Chemical Society (ACS) in ChemRxiv
In silico exploration of pyrocannabinoid interactions with key protein targets
Cannabinoids, particularly those derived from cannabis, have attracted considerable attention in recent years for their therapeutic potential in treating various diseases and ailments. In this study, we identified cannabinoid byproducts that result from the combustion of cannabidiol (CBD) - henceforth referred to as pyrocannabinoids - and employed molecular docking simulations to investigate their interactions with key protein targets implicated in different physiological processes. Specifically, we focused on peroxisome proliferator-activated receptor gamma (PPAR-γ), p21-activated kinase 1 (PAK1), CB1, CB2, and GPR119 proteins, elucidating the binding modes and affinities of pyrocannabinoid byproducts to these receptors. This investigation was done in collaboration with Real Isolates LLC. Our findings revealed diverse ligand-protein interactions, with some pyrocannabinoids displaying favorable binding energies and stable ligand-protein complexes. However, variations in binding affinities across different proteins underscored the complex pharmacological profiles of the pyrocannabinoids. Furthermore, the prediction of adsorption, distribution, metabolism, excretion and toxicity (ADMET) properties highlighted both promising and concerning aspects of cannabinoid pharmacokinetics, emphasizing the need for thorough preclinical evaluation. Additionally, our investigation into potential metabolic sites using cytochrome P450 enzymes provided insights into cannabinoid metabolites. Overall, our study contributes to the understanding of pyrocannabinoid pharmacology and informs the rational design of pyrocannabinoid-based therapeutics. Further experimental validation is warranted to translate these findings into clinically relevant applications.
- 10 June 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessIn silico exploration of pyrocannabinoid interactions with key protein targets
Cannabinoids, particularly those derived from cannabis, have attracted considerable attention in recent years for their therapeutic potential in treating various diseases and ailments. In this study, we identified cannabinoid byproducts that result from the combustion of cannabidiol (CBD) - henceforth referred to as pyrocannabinoids - and employed molecular docking simulations to investigate their interactions with key protein targets implicated in different physiological processes. Specifically, we focused on peroxisome proliferator-activated receptor gamma (PPAR-γ), p21-activated kinase 1 (PAK1), CB1, CB2, and GPR119 proteins, elucidating the binding modes and affinities of pyrocannabinoid byproducts to these receptors. This investigation was done in collaboration with Real Isolates LLC. Our findings revealed diverse ligand-protein interactions, with some pyrocannabinoids displaying favorable binding energies and stable ligand-protein complexes. However, variations in binding affinities across different proteins underscored the complex pharmacological profiles of the pyrocannabinoids. Furthermore, the prediction of adsorption, distribution, metabolism, excretion and toxicity (ADMET) properties highlighted both promising and concerning aspects of cannabinoid pharmacokinetics, emphasizing the need for thorough preclinical evaluation. Additionally, our investigation into potential metabolic sites using cytochrome P450 enzymes provided insights into cannabinoid metabolites. Overall, our study contributes to the understanding of pyrocannabinoid pharmacology and informs the rational design of pyrocannabinoid-based therapeutics. Further experimental validation is warranted to translate these findings into clinically relevant applications.
- Open Access
- 6 March 2024
- Published by MDPI AG in Preprints.org
An HPLC Method for Separation of Delta 9 THC from Delta 8 THC
The surge in popularity of Delta-8 Tetrahydrocannabinol (D8-THC) products, coupled with a lack of stringent regulation and oversight, has given rise to concerns regarding consumer safety and compliance with existing laws. This article delves into the challenges posed by the unregulated sale of D8-THC products, emphasizing the potential for contamination with prohibited constituents, including Delta-9 Tetrahydrocannabinol (D9-THC). The 2018 Farm Bill dictates that D9-THC concentrations must not exceed 0.3%, necessitating precise testing methods for accurate validation. Existing testing procedures, particularly involving High-Performance Liquid Chromatography (HPLC), face difficulties in distinguishing between D8 and D9 peaks, necessitating adjustments in parameters to enhance accuracy. The development of more refined testing methodologies is crucial for companies to ensure compliance, prevent adverse health effects, and provide consumers with accurately characterized cannabinoid profiles in the products they purchase.
- 6 March 2024
- Published by MDPI AG in Preprints.org
Open AccessAn HPLC Method for Separation of Delta 9 THC from Delta 8 THC
The surge in popularity of Delta-8 Tetrahydrocannabinol (D8-THC) products, coupled with a lack of stringent regulation and oversight, has given rise to concerns regarding consumer safety and compliance with existing laws. This article delves into the challenges posed by the unregulated sale of D8-THC products, emphasizing the potential for contamination with prohibited constituents, including Delta-9 Tetrahydrocannabinol (D9-THC). The 2018 Farm Bill dictates that D9-THC concentrations must not exceed 0.3%, necessitating precise testing methods for accurate validation. Existing testing procedures, particularly involving High-Performance Liquid Chromatography (HPLC), face difficulties in distinguishing between D8 and D9 peaks, necessitating adjustments in parameters to enhance accuracy. The development of more refined testing methodologies is crucial for companies to ensure compliance, prevent adverse health effects, and provide consumers with accurately characterized cannabinoid profiles in the products they purchase.
- Open Access
- 17 January 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Ultrasonic or Microwave Modified Continuous Flow Chemistry for The Synthesis of Tetrahydrocannabinol: Observing Effects Of Various Solvents And Acids
Synthesizing tetrahydrocannabinol is a lengthy process with minimal yields and little applicability on an industrial scale. To close the gap between bench chemistry and industry process chemistry, this paper introduces a small-scale flow chemistry method that utilizes a microwave or ultrasonic medium to produce major tetrahydrocannabinol isomers. This process produces excellent yields and minimal side products, which leads to more efficient large-scale production of desired cannabinoids.
- 17 January 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessUltrasonic or Microwave Modified Continuous Flow Chemistry for The Synthesis of Tetrahydrocannabinol: Observing Effects Of Various Solvents And Acids
Synthesizing tetrahydrocannabinol is a lengthy process with minimal yields and little applicability on an industrial scale. To close the gap between bench chemistry and industry process chemistry, this paper introduces a small-scale flow chemistry method that utilizes a microwave or ultrasonic medium to produce major tetrahydrocannabinol isomers. This process produces excellent yields and minimal side products, which leads to more efficient large-scale production of desired cannabinoids.
- Open Access
- 10 January 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Decoding the Molecular Dance: In Silico Exploration of Cannabinoid Interactions with Key Protein Targets for Therapeutic Insights
As hemp-based cannabinoids are continuously gaining popularity, synthesis and extraction methods for these compounds are ever-changing. Within the cannabinoid market, hydrogenated derivatives are also gaining popularity at an accelerated rate, with the need for in-depth analysis of these compounds pertinent to increasing the knowledge of cannabis chemistry. Our lab used Schrödinger to dock natural and synthetic cannabinoids in various CB1 and CB2 receptors, PPAR-γ, PAK1, and GPR119 complex including several enzymes, to evaluate the interacting residues within the known binding pockets, comprising the computation of binding energies, predicting ADME characteristics, and evaluating P450 sites of metabolism. The purpose of identifying active residues, sites of metabolism, and ADME characteristics for 40 various cannabinoids is to provide guidance in computer-aided drug design and rationalization in designing and synthesis of analogs.
- 10 January 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDecoding the Molecular Dance: In Silico Exploration of Cannabinoid Interactions with Key Protein Targets for Therapeutic Insights
As hemp-based cannabinoids are continuously gaining popularity, synthesis and extraction methods for these compounds are ever-changing. Within the cannabinoid market, hydrogenated derivatives are also gaining popularity at an accelerated rate, with the need for in-depth analysis of these compounds pertinent to increasing the knowledge of cannabis chemistry. Our lab used Schrödinger to dock natural and synthetic cannabinoids in various CB1 and CB2 receptors, PPAR-γ, PAK1, and GPR119 complex including several enzymes, to evaluate the interacting residues within the known binding pockets, comprising the computation of binding energies, predicting ADME characteristics, and evaluating P450 sites of metabolism. The purpose of identifying active residues, sites of metabolism, and ADME characteristics for 40 various cannabinoids is to provide guidance in computer-aided drug design and rationalization in designing and synthesis of analogs.
- Open Access
Saturated Cannabinoids: Update on Synthesis Strategies and Biological Studies of These Emerging Cannabinoid Analogs
Natural and non-natural hexahydrocannabinols (HHC) were first described in 1940 by Adam and in late 2021 arose on the drug market in the United States and in some European countries. A background on the discovery, synthesis, and pharmacology studies of hydrogenated and saturated cannabinoids is described. This is harmonized with a summary and comparison of the cannabinoid receptor affinities of various classical, hybrid, and non-classical saturated cannabinoids. A discussion of structure–activity relationships with the four different pharmacophores found in the cannabinoid scaffold is added to this review. According to laboratory studies in vitro, and in several animal species in vivo, HHC is reported to have broadly similar effects to Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive substance in cannabis, as demonstrated both in vitro and in several animal species in vivo. However, the effects of HHC treatment have not been studied in humans, and thus a biological profile has not been established.
Open AccessSaturated Cannabinoids: Update on Synthesis Strategies and Biological Studies of These Emerging Cannabinoid Analogs
Natural and non-natural hexahydrocannabinols (HHC) were first described in 1940 by Adam and in late 2021 arose on the drug market in the United States and in some European countries. A background on the discovery, synthesis, and pharmacology studies of hydrogenated and saturated cannabinoids is described. This is harmonized with a summary and comparison of the cannabinoid receptor affinities of various classical, hybrid, and non-classical saturated cannabinoids. A discussion of structure–activity relationships with the four different pharmacophores found in the cannabinoid scaffold is added to this review. According to laboratory studies in vitro, and in several animal species in vivo, HHC is reported to have broadly similar effects to Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive substance in cannabis, as demonstrated both in vitro and in several animal species in vivo. However, the effects of HHC treatment have not been studied in humans, and thus a biological profile has not been established.
- Open Access
- 3 August 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Saturated Cannabinoids: Update on synthesis strategies and biological studies of these emerging cannabinoid analogs.
Natural and non-natural hexahydrocannabinols (HHC) were first described in 1940 by Adam and in late 2021 arose on the drug market in the United States and in some European countries. A background on the discovery, synthesis, and pharmacology studies of hydrogenated and saturated cannabinoids is described. This is harmonized with a summary and comparison of the cannabinoid receptor affinities of various classical, hybrid, and non-classical saturated cannabinoids. A discussion of structure-activity relationships with the four different pharmacophores found in the cannabinoid scaffold is added to this review. According to laboratory studies in vitro, and in several animal species in vivo, HHC is reported to have broadly similar effects to Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive substance in cannabis, as demonstrated both in vitro and in several animal species in vivo. However, the effects of HHC treatment have not been studied in humans, and thus a biological profile has not been established.
- 3 August 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessSaturated Cannabinoids: Update on synthesis strategies and biological studies of these emerging cannabinoid analogs.
Natural and non-natural hexahydrocannabinols (HHC) were first described in 1940 by Adam and in late 2021 arose on the drug market in the United States and in some European countries. A background on the discovery, synthesis, and pharmacology studies of hydrogenated and saturated cannabinoids is described. This is harmonized with a summary and comparison of the cannabinoid receptor affinities of various classical, hybrid, and non-classical saturated cannabinoids. A discussion of structure-activity relationships with the four different pharmacophores found in the cannabinoid scaffold is added to this review. According to laboratory studies in vitro, and in several animal species in vivo, HHC is reported to have broadly similar effects to Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive substance in cannabis, as demonstrated both in vitro and in several animal species in vivo. However, the effects of HHC treatment have not been studied in humans, and thus a biological profile has not been established.
- Open Access
- 1 January 2023
- Published by Begell House Inc. Publishers in International Journal of Medicinal Mushrooms
- Vol. 25 (9) , 1-10
Psychoactive Isoxazoles, Muscimol, and Isoxazole Derivatives from the Amanita (Agaricomycetes) Species: Review of New Trends in Synthesis, Dosage, and Biological Properties
Herbal products found in nature can serve as great systems of study for drug design. The Amanita muscaria mushroom is native to many parts of the Northern Hemisphere and has a very distinctive appearance with its red cap and white spotted warts. The mushroom comprises several pharmacologically active alkaloids, including muscazone, muscarine, ibotenic acid, and muscimol, the latter two compounds being potent GABA agonists. Muscimol has served as a backbone in the design of GABA agonists devoid of effects on the GABA-metabolizing enzyme, GABA transaminase, and GABA uptake systems. In this sense, several analogs of muscimol have been synthesized and studied including THIP, THPO, iso-THIP, iso-THAZ and 4-PIOL which all interact with the GABA receptors much differently. The growing pharmacological and toxicological interest based on many conflicting opinions on the use of the neuroprotective role of muscimol analogs against some neurodegenerative diseases, its potent role in the treatment of cerebral ischemia and other socially significant health conditions provided the basis for this review.
- 1 January 2023
- Published by Begell House Inc. Publishers in International Journal of Medicinal Mushrooms
- Vol. 25 (9) , 1-10
Open AccessPsychoactive Isoxazoles, Muscimol, and Isoxazole Derivatives from the Amanita (Agaricomycetes) Species: Review of New Trends in Synthesis, Dosage, and Biological Properties
Herbal products found in nature can serve as great systems of study for drug design. The Amanita muscaria mushroom is native to many parts of the Northern Hemisphere and has a very distinctive appearance with its red cap and white spotted warts. The mushroom comprises several pharmacologically active alkaloids, including muscazone, muscarine, ibotenic acid, and muscimol, the latter two compounds being potent GABA agonists. Muscimol has served as a backbone in the design of GABA agonists devoid of effects on the GABA-metabolizing enzyme, GABA transaminase, and GABA uptake systems. In this sense, several analogs of muscimol have been synthesized and studied including THIP, THPO, iso-THIP, iso-THAZ and 4-PIOL which all interact with the GABA receptors much differently. The growing pharmacological and toxicological interest based on many conflicting opinions on the use of the neuroprotective role of muscimol analogs against some neurodegenerative diseases, its potent role in the treatment of cerebral ischemia and other socially significant health conditions provided the basis for this review.
- Open Access
- 21 December 2022
- Published by American Chemical Society (ACS) in ChemRxiv
Antineoplastic Properties of THCV, HHC and their anti-Proliferative effects on HPAF-II, MIA-paca2, Aspc-1, and PANC-1 PDAC Pancreatic Cell Lines
Cannabinoid receptors CB1 and CB2 are the primary endogenous receptors with which cannabinoids interact, inducing physiological and psychological effects. Although interactions with other receptors including TRPV1 and GPCR55, have been recognized in earlier studies, these interactions may play a significant role in cancer remediation through the unspecified upregulation or downregulation of specific pathways. The main active constituents within the cannabis plant are cannabidiol (CBD) and tetrahydrocannabinol (THC), which have been categorized as either non-intoxicating with benefit or intoxicating with no benefit. These categories are constantly ignored, as cannabinoids have shown efficacy in the treatment of certain diseases and ailments as single-agent compounds. Tetrahydrocannabivarin (THCV), a rare cannabinoid, is a homologue of THC, with the C5 alkyl chain having three carbons rather than the standard five carbon length. THCV has garnered attention in a clinical setting as an anti-obesity drug treating glucose issues. Hexahydrocannabinol (HHC), a hydrogenated analogue of THC, is a rare cannabinoid like THCV. These cyclic cannabinoids are considered rare, because they are typically found in minimal to trace amounts within cannabis sativa and their given C. indica, and C. ruderalis sub species. Increased popularity of these rare cannabinoids has led to proposed experimentation leading to assessing the cytotoxicity of these cannabinoids toward, cancer cells of the pancreas (MIA-PaCa2, HPAF-II, and PANC1). The data evaluated through such studies led to the proposed idea of these rare cyclic cannabinoids towards the treatment of pancreatic cancer due to the modest efficacy as single agent antineoplastics compared to common single agent antineoplastics on the market, with evidence being strongly presented when compared to commercially available anticancer agents poly(ADP-ribose) polymerase (PARP) inhibitors.
- 21 December 2022
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAntineoplastic Properties of THCV, HHC and their anti-Proliferative effects on HPAF-II, MIA-paca2, Aspc-1, and PANC-1 PDAC Pancreatic Cell Lines
Cannabinoid receptors CB1 and CB2 are the primary endogenous receptors with which cannabinoids interact, inducing physiological and psychological effects. Although interactions with other receptors including TRPV1 and GPCR55, have been recognized in earlier studies, these interactions may play a significant role in cancer remediation through the unspecified upregulation or downregulation of specific pathways. The main active constituents within the cannabis plant are cannabidiol (CBD) and tetrahydrocannabinol (THC), which have been categorized as either non-intoxicating with benefit or intoxicating with no benefit. These categories are constantly ignored, as cannabinoids have shown efficacy in the treatment of certain diseases and ailments as single-agent compounds. Tetrahydrocannabivarin (THCV), a rare cannabinoid, is a homologue of THC, with the C5 alkyl chain having three carbons rather than the standard five carbon length. THCV has garnered attention in a clinical setting as an anti-obesity drug treating glucose issues. Hexahydrocannabinol (HHC), a hydrogenated analogue of THC, is a rare cannabinoid like THCV. These cyclic cannabinoids are considered rare, because they are typically found in minimal to trace amounts within cannabis sativa and their given C. indica, and C. ruderalis sub species. Increased popularity of these rare cannabinoids has led to proposed experimentation leading to assessing the cytotoxicity of these cannabinoids toward, cancer cells of the pancreas (MIA-PaCa2, HPAF-II, and PANC1). The data evaluated through such studies led to the proposed idea of these rare cyclic cannabinoids towards the treatment of pancreatic cancer due to the modest efficacy as single agent antineoplastics compared to common single agent antineoplastics on the market, with evidence being strongly presented when compared to commercially available anticancer agents poly(ADP-ribose) polymerase (PARP) inhibitors.